Bacteria can become resistant to antibiotics via three mechanisms: antibiotic inactivation, target modification, and alteration of intracellular antibiotic concentration. The latter mechanism can occur by either decreasing permeability to an antibiotic or increasing the activities of a variety of efflux pumps. While permeability is a significant barrier to antibiotics in gram-negative bacteria due to the presence of an outer membrane, it is an unlikely mechanism of resistance for grampositive bacteria, since they lack an outer membrane. Efflux of antibiotics is a clinically significant general resistance mechanism for bacteria, often endowing organisms with multipledrug-resistant (MDR) phenotypes (14) . Gram-positive and gram-negative bacteria can possess multiple chromosomal and plasmid-encoded efflux pumps with broad substrate specificities, including both naturally and synthetically produced antibiotics (2, 24, 30) . For example, an analysis of the genome sequence of methicillin-resistant Staphylococcus aureus N315 indicates that there are Ͼ20 open reading frames capable of encoding antibiotic efflux pumps (16; http://www.membranetransport.org).
For gram-negative bacteria, pumps belonging to the resistance-nodulation-cell division family play the greatest role in contributing to resistance to many clinically used antibiotics. Examples of this class of efflux pumps include the AcrB pump in Escherichia coli and the MexB, MexD, MexF, and MexY pumps in Pseudomonas aeruginosa (2, 30) . To date, resistancenodulation-cell division pumps have not been described for gram-positive organisms. For gram-positive bacteria, pumps belonging to the major facilitator superfamily class play the greater role in the efflux of clinically relevant antibiotics, contributing to resistance. Major facilitator superfamily pumps are found in both prokaryotes and eukaryotes, including mammals, and prokaryotic examples of this class of efflux pumps include the NorA pump of S. aureus (28) , the PmrA pump of Streptococcus pneumoniae (9) , and the EmeA pump of Enterococcus faecalis (18) . Recent reports have described the crystal structures of the E. coli AcrB pump (25, 36) and the Bacillus subtilis BmrR MDR transcriptional activator (37) , both cocomplexed with substrates, and the outer membrane transporter TolC (15) . While structural details provide the basis for substrate recognition, the mechanism by which molecules are actually transported to the outside of a cell remains to be elucidated.
Inhibition of efflux is potentially one way to improve the clinical efficacy of an antibiotic, even in the presence of targetbased mutations, by increasing intracellular antibiotic concentrations. Because of emerging resistance to all classes of antibiotics, in particular the fluoroquinolones, there has been a significant focus by the pharmaceutical industry on addressing this problem (17) . Reserpine, a plant alkaloid, is a known inhibitor of both mammalian and gram-positive bacterial efflux. However, its clinical utility is limited by its neurotoxicity (27) . It has activity against the NorA pump of S. aureus (22) , a known contributor to fluoroquinolone resistance in clinical isolates (12, 23) . Homologs of the NorA pump are found in multiple gram-positive bacteria, suggesting that reserpine and other NorA pump inhibitors would inhibit the antibiotic pumps of other clinical pathogens. In this study, the activities in bacteria of two novel mammalian MDR inhibitors, VX-710 and VX-853 ( Fig. 1) , were evaluated. VX-710 and VX-853 are novel small molecules that inhibit mammalian MDR and confer increased drug sensitivity to cells expressing both P-glycoprotein and MRP-1 (5, 6, 7), with minimal in vivo toxicity (4, 29, 33, 35) . Results show that both VX-710 and VX-853 potentiate the activities of multiple antibiotics in several gram-positive pathogens, suggesting that these compounds represent a new class of bacterial efflux inhibitors with potential for use in combination antibiotic therapy.
MATERIALS AND METHODS
Compounds. VX-710 and VX-853 ( Fig. 1) were obtained from in-house stocks. The compounds were dissolved in 100% dimethyl sulfoxide (DMSO) at a con-centration of 100 mg/ml and stored at Ϫ20°C. Reserpine was obtained from Sigma Chemical Co. (St. Louis, Mo.), and stocks were stored as described above. All antibiotics were obtained from standard commercial sources, and stocks were prepared at 25.6 mg/ml in 100% DMSO and stored at Ϫ20°C.
Bacterial strains. S. aureus ATCC 29213, E. faecalis ATCC 29212, and S. pneumoniae ATCC 10015 were obtained from the American Type Culture Collection (Manassas, Va.). S. aureus strains SA-1199 (clinical isolate; susceptible), SA-1199B (SA-1199; NorA overproducer, also has an A116E GrlA mutation), SA-8325-4 (NCTC 8325 cured of prophages), and SA-K2068 (SA-8325-4; nonNorA multidrug efflux pump overproducer mutation) were all gifts from Glenn Kaatz (10, 11, 13) .
Antibacterial assays. MICs were determined by two or more independent tests using microdilution techniques according to the NCCLS guidelines (26) in cation-adjusted Mueller Hinton broth (caMHB; Fisher Scientific, Pittsburgh, Pa.). Sterile laked horse blood (3%; Quad Five, Ryegate, Mont.) was added to assays for E. faecalis and S. pneumoniae. A final concentration of 1% DMSO was present in all assays, a concentration which had no antibacterial effect on its own. The MICs for the quality control strains, S. aureus ATCC 29213, E. faecalis ATCC 29212, and S. pneumoniae ATCC 10015, were within the NCCLS ranges (26) . MIC 90 studies. Susceptibility studies with large panels of resistant clinical isolates to determine the MICs at which 90% of the isolates tested were inhibited (MIC 90 s) were performed at Focus Technologies, Herndon, Va., according to NCCLS protocols (26) . VX-710 and VX-853 were used at 50 g/ml in combination with norfloxacin and ciprofloxacin in the presence of 1% DMSO.
Determination of the MECs of EPIs. The MIC of an efflux substrate was determined in the presence of increasing amounts of efflux pump inhibitors (EPIs; 0 to 100 g of EPI/ml in serial twofold dilutions). The minimal effective concentration (MEC) was determined to be the minimal concentration of EPI that produced the maximal reduction in substrate MIC. No further decrease in substrate MIC was observed at EPI concentrations greater than the MEC.
EtBr efflux. Ethidium bromide (EtBr) efflux assays with S. aureus were performed using the method described by Markham et al. (22) . Mid-logarithmicphase S. aureus ATCC 29213 cells, grown in caMHB medium, were loaded with 10 g of EtBr/ml in the presence of 25 g of reserpine/ml to inhibit efflux during loading. Cells were incubated at 37°C for 20 min and then pelleted by centrifugation. The medium was decanted, and the cell pellet was resuspended in fresh caMHB medium, either with or without an EPI, to an optical density at 600 nm of 0.2. EtBr efflux was determined by continuously monitoring fluorescence at excitation and emission wavelengths of 530 and 600 nm in a black 96-well polystyrene plate with a clear, flat bottom (3904; Costar, Cambridge, Mass.) by using a SpectraMax Gemini spectrofluorimeter (Molecular Devices, Sunnyvale, Calif.). Results are presented as the average from three individual replicate experiments.
RESULTS

Effect of VX-710 and VX-853 on the MICs of EtBr for S.
aureus, E. faecalis, and S. pneumoniae. For the initial evaluation of VX-710 and VX-853 in bacteria, EtBr was used as a test substrate. Since EtBr is a nonspecific DNA intercalator, the only known mechanism of resistance to EtBr is via efflux (22) .
Standard MIC assays for measuring the activity of EtBr were performed in the presence and absence of increasing concentrations of EPIs (0 to 100 g/ml). Neither VX-710 nor VX-853 at 100 g/ml had intrinsic activity against S. aureus, E. faecalis, and S. pneumoniae, while reserpine had an MIC of 50 g/ml against S. pneumoniae ( Table 1 ). The MEC for inhibition of EtBr efflux was defined as the lowest amount of EPI which produces the maximum effect on the MIC of a given antibiotic; no further potentiating activity was observed above the MEC (Table 1) . Similar to reserpine, the MIC of EtBr was markedly reduced in the presence of VX-710 and VX-853. This reduction was apparent for all three organisms to different degrees (2-to 31-fold reductions in EtBr MICs) ( Table 1) . Interestingly, the activity of VX-710 was nonsaturable at Ն100 g/ml in S. aureus, E. faecalis, and S. pneumoniae; increasing amounts of VX-710 produced a greater reduction in EtBr MICs. This effect was also observed for reserpine in E. faecalis. For further experiments with EtBr and other antibiotics, unless otherwise noted, VX-710 was used at 100 g/ml, its maximum solubility limit. Note that since reserpine possessed an intrinsic activity against S. pneumoniae at higher concentrations, it is possible that the 50-fold reduction in the MIC of EtBr in the presence of the maximal subinhibitory concentration of reserpine (25 g/ml) is due in part to a combination of the activities of reserpine and EtBr.
Inhibition of EtBr efflux in S. aureus ATCC 29213 by VX-710 and VX-853. The ability of VX-710 and VX-853 to directly inhibit the efflux of EtBr in S. aureus was evaluated by using a fluorescence assay (22) . Since EtBr fluoresces only when it is bound to nucleic acid inside cells, a time-dependent decrease in fluorescence of EtBr-loaded bacteria is due to active efflux. All EPIs were used at four times the MEC for EtBr (Table 1) , a saturating concentration in S. aureus ATCC 29213, except for VX-710, which was used at 100 g/ml. Results presented in a EPIs were used at the MEC, except for VX-710, which was used at its solubility limit, 100 g/ml.
b Maximal subihibitory concentration of reserpine. (Table 2) . Results showed that, similar to reserpine, VX-710 and VX-853 lowered the MICs of levofloxacin, ciprofloxacin, norfloxacin, gentamicin, novobiocin, tetracycline, and tetraphenylphosphonium bromide reproducibly by two-to fourfold. No effect was observed on the MICs of gatifloxacin, erythromycin, azithromycin, chloramphenicol, ceftriaxone, and linezolid. The results presented in Table 2 reflect the ability of EPIs to inhibit the normal level of antibiotic efflux expression in S. aureus ATCC 29213 in the absence of induction by prior antibiotic exposure or any mutation conferring overexpression of efflux pumps.
Hydrophilic fluoroquinolones such as norfloxacin and ciprofloxacin are well-known substrates for the NorA pump and several other less well-characterized pumps in S. aureus (10, 13) . On the other hand, the more recent hydrophobic fluoroquinolones, such as gatifloxacin and moxifloxacin, are poorer substrates for NorA. Recently, one other pump in S. aureus which also recognizes the hydrophobic fluoroquinolones has been described (10) . To investigate the potential of VX-710 and VX-853 to block the efflux of several fluoroquinolones in cells with constitutively overexpressed efflux pumps, we used S. aureus strains SA-1199B and SA-K2068 (Table 3 ). All EPIs were used at four times the MEC determined for EtBr efflux in S. aureus ATCC 29213, except for VX-710, which was used at 100 g/ml, its maximal solubility limit. Results showed that for a NorA-overproducing strain (SA-1199B), VX-853 and VX-710 were effective in reducing MICs by 8-and 32-fold for norfloxacin, 2-and 8-fold for ciprofloxacin, 2-and 4-fold for gatifloxacin, and 1-and 2-fold for levofloxacin, respectively. For a non-NorA MDR pump-overproducing strain (SA-K2068), VX-853 and VX-710 were also effective in reducing the norfloxacin MICs by two-and eightfold, the ciprofloxacin MICs by four-and eightfold, the gatifloxacin MICs by two-and fourfold, and the levofloxacin MICs by twofold (both compounds), respectively. These results show that VX-853 and VX-710 are capable of potentiating the antibacterial activities of fluoroquinolones even in the presence of overexpressed efflux proteins, a likely scenario in clinical S. aureus isolates. Note that substantial reduction of fluoroquinolone MICs occurred in SA-1199B, which in addition to overexpressing NorA also contains a fluoroquinolone-resistant target-based mutation in grlA (A116E) (11) .
Effects of VX-710 and VX-853 on the fluoroquinolone susceptibilities of S. aureus and E. faecalis clinical isolate panels.
To be useful in combination therapy, an EPI needs to substan-
FIG. 2. Effect of EPIs on EtBr efflux in S. aureus ATCC 29213. S. aureus cells were loaded with EtBr as described in Materials and Methods.
EPIs were used at four times the MEC (25 g of reserpine/ml, long dashes; 100 g of VX-710/ml, short dashes; 6.25 g of VX-853/ml, solid thin line; and no EPI control, solid thick line). Fluorescence was continuously monitored over time at room temperature, and results are an average from three replicate experiments. The standard deviations at the end of the experiment, at 294 seconds, were the following (in fluorescence units): no EPI, Ϯ4.7; reserpine, Ϯ4.5; VX-710, Ϯ6.9; and VX-853, Ϯ11.3. a MEC is the minimal effective concentration determined for EtBr with ATCC 29213 (Table 1 ). The following concentrations were used: reserpine, 25 g/ml; VX-710, 100 g/ml; VX-853, 6.25 g/ml.
b Results were reproduced in a minimum of two independent experiments.
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on August 28, 2017 by guest http://aac.asm.org/ tially reduce the MIC of an antibiotic to within the range of clinical susceptibility. Because many different resistance mechanisms are often present in clinical isolates, including multiple target-based mutations in addition to efflux mutations, the barrier to antibiotic efficacy is much greater. We examined the activities of VX-710 and VX-853, each at 50 g/ml, in potentiating the activities of two fluoroquinolones, norfloxacin and ciprofloxacin, against panels of clinical isolates of S. aureus and E. faecalis, including several high-level fluoroquinolone-resistant mutants (Table 4) . This relatively high concentration of EPI approached the solubility limit for both compounds and was chosen to maximize the chance of observing an effect in combination with antibiotics against isolates with multiple resistance mechanisms. Oxacillin and vancomycin MICs were also determined in order to identify which isolates were methicillin resistant (S. aureus) and vancomycin resistant (E. faecalis). Among the S. aureus isolates (Table 4) , Ͼ2-fold decreases in the MICs of ciprofloxacin (10 of 15 isolates) and norfloxacin (13 of 15 isolates) in combination with VX-710 were observed; no significant (Ͼ2-fold) decrease in the MIC was seen with VX-853. Interestingly, significant increases in ciprofloxacin (isolates 3 and 5) and norfloxacin (isolates 3, 6, and 9) MICs in combination with VX-853 were observed for several S. aureus isolates, while reductions in MICs occurred with VX-710 for the same isolates. The reason for this phenomenon is unclear. Less of an effect was observed with both VX-710 and VX-853 and the E. faecalis isolates tested (Table 4) ; however, a twofold trend in the reduction of MICs of ciprofloxacin and norfloxacin in combination with VX-710 was observed, and a similar trend was less apparent with VX-853. While VX-710 was generally more active in S. aureus than in E. faecalis, the activity was still insufficient to restore clinical susceptibility to the highly fluoroquinolone-resistant strains in the panel. VX-710 did significantly impact the fluoroquinolone MICs (4-to Ͼ8-fold) for the more susceptible S. aureus strains in the panel, suggesting a possible use in combination with fluoroquinolones in treating susceptible isolates.
DISCUSSION
One natural role of efflux pumps in prokaryotic and eukaryotic cells is to remove toxins from the interior of the cell. This protective function enables bacterial cells to survive in hostile environments, including the presence of antibiotics during the treatment of infections. The up-regulation of efflux systems through physiological induction and spontaneous mutation can significantly lower the intracellular concentration of many antibiotics, causing an impact on clinical efficacy. For this reason, many academic and pharmaceutical programs have focused on identifying inhibitors of gram-negative and gram-positive efflux systems that could potentially be used in combination with antibiotics to improve efficacy and suppress resistance (1, 2, 3, 8, 10, 21, 31, 34) . In vitro, EPIs have been shown to reduce spontaneous resistance frequencies to antibiotics in P. aeruginosa (19) , S. pneumoniae (20) , and S. aureus (21, 22) . In an animal model of P. aeruginosa infection, Renau et al. (32) showed that levofloxacin plus an EPI was more efficacious than levofloxacin alone, demonstrating the potential for combination therapy in vivo.
While there is limited structural homology between bacterial and mammalian efflux systems, there is significant substrate overlap (2, 27) . Because of this overlap, it is not surprising that many mammalian MDR inhibitors, such as reserpine, verapamil, and GG918, also affect bacterial efflux (1, 8, 27) . In this study, we have shown that two novel mammalian MDR inhibitors were active in potentiating the activity of EtBr against S. aureus, E. faecalis, and S. pneumoniae (Table 1) . Since EtBr is a substrate of many different bacterial pumps, the number of pumps these EPIs are acting on in each organism is unknown. In the case of other antibiotics, it is also not clear whether the potentiating activities of VX-710 and VX-853 are due to the inhibition of one or more pumps (Table 2 ). For S. aureus, however, we have demonstrated that both VX-710 and VX-853 can partially reverse fluoroquinolone resistance conferred by the overexpression of at least two different pumps (Table 3) . Furthermore, it is interesting that the activity of VX-710 on the MIC of EtBr was nonsaturable for S. aureus, E. faecalis, and S. pneumoniae, which might suggest the targeting of multiple efflux pumps.
The in vitro data reported here suggest that VX-710 and VX-853 are representatives of a novel class of bacterial EPIs that should be explored for their clinical potential. We observed that VX-710 was consistently more active than VX-853. However, in combination with ciprofloxacin and norfloxacin, VX-710 still fell short of restoring fluoroquinolone susceptibility to highly resistant clinical isolates (Table 4) . These results do not rule out the possibility that other derivatives of this EPI class may be more effective in completely blocking fluoroquinolone efflux or that VX-710 may be more effective in combi- nation with other quinolone antibiotics. It is also possible that some highly resistant strains have acquired too many targetbased mutations in topoisomerase IV and/or DNA gyrase, making it difficult, even with an ideal EPI, to achieve sufficient intracellular antibiotic concentrations to overcome the reduction in target binding affinity. One advantage of this new class of EPIs is that VX-710 has already been evaluated for safety in the clinic and in combination with chemotherapeutic agents for cancer therapies. In these studies, only mild adverse events were observed with VX-710 (4, 29, 33, 35) compared to other EPIs (31) . Furthermore, in bacteria, VX-710 and VX-853 have no intrinsic antibacterial activity, thereby demonstrating the specificity of their pharmacological effect. While VX-710 and VX-853 have been shown to be active in gram-positive organisms, preliminary data with gram-negative organisms suggest that more bacterially permeable derivatives of this compound class could extend their usefulness to inhibiting gram-negative bacterial efflux mechanism(s) (data not shown).
It has been speculated that bacterial antibiotic EPIs with mammalian MDR activity may manifest toxicities in the clinic (17) ; proof of this remains to be demonstrated. In fact, a well-tolerated dually active bacterial and mammalian EPI may have some favorable pharmacological effects, such as the following: (i) promoting gastrointestinal absorption of antibiotic (raising plasma levels); (ii) improving permeation of the bloodbrain barrier for central nervous system infections; (iii) increasing mammalian intracellular antibiotic concentrations for the eradication of invasive pathogens; and (iv) enabling the use of lower concentrations of antibiotics to minimize their undesirable side effects. Such effects could significantly improve antibiotic efficacy by raising physiological levels of an antibiotic and act synergistically by reducing bacterial efflux. The potential clinical utility of this new class of bacterial efflux inhibitors as potentiators of antibiotic activity warrants further investigation.
